Pharmaceuticals

AbbVie Presents New Data for Two Antibody-Drug Conjugates in Multiple Indications at ASCO 2024

bexib
By bexib 0 Min Read

In an interview with Pharm Exec associate editor Don Tracy, Pedro Valencia, vice president of solid tumor pipeline strategy and execution at AbbVie, discusses the ABBV-400 and ABBV-706 data from multiple studies presented at ASCO.

You Might Also Like

Books to Read to Become a Leader: 6 Books Trusted by Pharmaceutical Executives

FDA Approves Arcutis Biotherapeutics’ Xolive for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis

National HIV Testing Day 2024: Boost your self-love and check your status

NHS platform announces it will accelerate clinical trials for personalised cancer vaccines

Theramex’s Eladinos is recommended by NICE for postmenopausal bone disease

Share This Article
Previous Article E-commerce in Brazil: Growth despite obstacles
Next Article Ready to slice: Today’s menu of featured 3D printing slicer software
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Local SEO vs. Ecommerce SEO Puzzle
Retail & E-commerce
Singapore’s GFTN partners with Odisha to establish fintech hub
Fintech
Lazada and Peak3 bring digital insurance to over 5 million people in Southeast Asia
Fintech
Mandarin Oriental’s international chef praises Williams’ global credibility
Hospitality & Tourism